Ultraviolet B Phototherapy

UVB exposure creates DNA photoproducts in skin cells, which alter cellular activity and local immune signaling. These changes can reduce excessive inflammatory signaling and limit abnormal keratinocyte proliferation, a process relevant to disorders in which inflammation or rapid epidermal growth contributes to disease. The treatment therefore acts through biologic changes within the skin rather than through simple surface warming or illumination.

The wavelength determines the form of UVB exposure delivered to the skin. Narrowband treatment commonly uses light around 311–313 nm, whereas broadband treatment uses a broader UVB spectrum. This distinction is important because treatment protocols specify the radiation type and dose together, allowing clinicians to adjust exposure according to the selected modality, skin type, and observed clinical response.

Response depends partly on how skin cells and local immune pathways react to the delivered radiation. UVB can modify immune signaling while reducing excessive inflammation and keratinocyte proliferation, but the required exposure is not identical for every patient. Skin type and clinical response therefore influence dose selection and scheduling, helping clinicians pursue therapeutic effects while limiting excessive erythema and cumulative damage.

Its effects on local immune signaling and keratinocyte proliferation are relevant to inflammatory conditions such as psoriasis and atopic dermatitis, while its medical use also includes the pigmentary disorder vitiligo. These applications reflect different clinical problems managed with the same controlled-light approach. The schedule and dose still require adjustment for the individual patient rather than assuming one regimen suits every disorder.

Treatment schedules are adjusted according to skin type and clinical response. A clinician must also select the UVB delivery form, such as narrowband or broadband radiation, and use controlled doses rather than an unrestricted exposure. Ongoing observation helps determine whether the regimen is producing the intended clinical effect while avoiding excessive erythema, premature skin aging, and cumulative ultraviolet damage.

Monitoring focuses on the patient’s clinical response and signs of excessive ultraviolet exposure, particularly erythema, which indicates skin redness or irritation. Longer-term concerns include premature skin aging and cumulative ultraviolet damage. These considerations make dose control and follow-up essential parts of treatment, because increasing exposure without monitoring could shift the balance away from therapeutic benefit and toward avoidable harm.

In medicine, UVB phototherapy is used for psoriasis, vitiligo, and atopic dermatitis. The approach is relevant across these conditions because it can influence inflammatory signaling and skin-cell behavior, although the clinical target differs between disorders. Treatment plans are individualized using skin type and response, while monitoring helps assess benefit and manage the risks associated with repeated ultraviolet exposure.